2002/4/EC: Commission Decision of 27 December 2001 on financial assistance from the Community for storage in France, Italy and the United Kingdom of antigen for production of foot-and-mouth disease vaccine (notified under document number C(2001) 4383)
Data as of 2026-07-04 Β· Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. Β· Read the official text β
1. The Community shall grant financial assistance to France for the stocking of antigen for the production of foot-and-mouth disease vaccine. 2. The "Agence Française de Securite Sanitaire des Aliments (AFSSA)" at Lyon in France shall hold the stock of antigen to which paragraph 1 relates. 3. The Community's financial assistance shall be up to a maximum of EUR 30000 for the period 1 January to 31 December 2001.
1. The Community shall grant financial assistance to Italy for the stocking of antigen for the production of foot-and-mouth disease vaccine. 2. The "Istituto Zooprofilattico Sperimentale di Brescia" in Italy shall hold the stock of antigen to which paragraph 1 relates. 3. The Community's financial assistance shall be up to a maximum of EUR 30000 for the period 1 January to 31 December 2001.
1. The Community shall grant Merial S.A.S. Pirbright, United Kingdom, financial assistance for the stocking of antigen for the production of foot-and-mouth disease vaccine. 2. Merial S.A.S. Pirbright, United Kingdom, shall hold the stock of antigen stored at the premises of Merial S.A.S. in accordance with contracts SANCO/161/2000 and SANCO/374/2000. 3. The Community's financial assistance shall be up to a maximum of EUR 26100 for the periods 19 April 2001 to 31 December 2001 and 1 February 2001 to 31 December 2001 respectively.
1. The Community's financial assistance referred to in Article 1(3) and Article 2(3) shall be paid following the presentation by the Member State concerned, and in the case of the financial assistance referred to in Article 3(3) following the presentation by Merial S.A.S., of supporting documents which demonstrate the effective completion of the tasks. 2. The supporting documents referred to in paragraph 1 must be presented to the Commission before 1 March 2002 and they shall include: (a) technical information on: - the amount and type of antigen stored (storage records), - storage equipment used (type, number and capacity of tanks), - security systems in place (temperature control, anti-theft measures), - insurance arrangements (fire, accidents); (b) financial information (completion of table as shown in the Annex).
This Decision is addressed to the Member States. Done at Brussels, 27 December 2001. For the Commission David Byrne Member of the Commission (1) OJ L 224, 18.8.1990, p. 19. (2) OJ L 203, 28.7.2001, p. 16. (3) OJ L 368, 31.12.1991, p. 21. (4) OJ L 66, 8.3.2001, p. 39. (5) OJ L 33, 8.2.2000, p. 21. (6) OJ L 160, 26.6.1999, p. 103.
>PIC FILE= "L_2002002EN.002102.TIF">
Source: EUR-Lex (Publications Office of the EU), Β© European Union, reuse permitted under Commission Decision 2011/833/EU.